HEALTHX · NSE
Health X Platform Limited
₹300
+0.00% (₹0)
Prev. close
₹300
Volume
1,400
Delivery %
82.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Health X Platform Limited
Health X Platform Limited operates a digital network of healthcare and portfolio management services in India. The company operates through the Financial Services and Healthcare Network segments. It is involved in the financing of loans; investment in shares and securities; and activities for pathology and marketing of healthcare and OTC products through e-commerce portal. The company also provides financial consultancy, professional fees, wealth management, financial planning, distribution, and related services, as well as diagnostic services, including pathological/radiological investigation. In addition, it operates digital platforms for healthcare, including the Sastasundar app, a consumer-focused digital healthcare platform consisting of pharmacy, diagnostics, and wellness; and retailershakti.com, a B2B digital platform for pharmaceutical and wellness products. The company was formerly known as Sastasundar Ventures Limited Limited and changed its name to Health X Platform Limited in February 2026. Health X Platform Limited was incorporated in 1989 and is based in Kolkata, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Banwari Lal Mittal
Headquarters
Kolkata
Employees
2,760
Website
sastasundarventures.comExchange
View on NSE ↗Key stats
Market cap
₹954.31 Cr
P/E ratio (TTM)
763.6
EPS (TTM)
₹-6.35
Beta (1Y · daily vs NIFTY 50)
0.81
Beta (5Y · monthly vs NIFTY 50)
0.81
Shares float
63.78 L
EPS · quarter ended Jun 2026
₹0.80
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹548.20 Cr | — | ₹1,039.82 Cr | ₹1,375.71 Cr | ₹1,110.95 Cr | ₹1,319.27 Cr | |
| EBITDA | — | — | ₹-113.19 Cr | ₹-20.35 Cr | ₹-197.62 Cr | ₹4.99 Cr |
| ₹-10.40 Cr | — | ₹-72.21 Cr | ₹8.88 Cr | ₹-91.17 Cr | ₹1.18 Cr | |
| Diluted EPS | ₹-3.27 | — | ₹-22.7 | ₹2.79 | ₹-28.66 | ₹0.37 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹293.00 Cr | ₹1,278.00 Cr | ₹1,204.00 Cr | ₹1,149.00 Cr | ₹970.00 Cr | ₹936.00 Cr | |
| — | ₹1.85 Cr | ₹9.33 Cr | ₹3.88 Cr | ₹91.90 L | ₹25.66 Cr | |
| Stockholders' equity | ₹200.00 Cr | ₹827.00 Cr | ₹754.00 Cr | ₹763.00 Cr | ₹670.00 Cr | ₹641.00 Cr |
Current assets, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-31.00 Cr | ₹-207.00 Cr | ₹-112.00 Cr | ₹36.00 Cr | ₹-17.00 Cr | ₹-74.00 Cr | |
| Investing cash flow | ₹21.37 Cr | — | ₹132.52 Cr | ₹-33.93 Cr | ₹-1.13 Cr | ₹171.19 Cr |
| ₹3.73 Cr | — | ₹-86.76 L | ₹-2.35 Cr | ₹-44.31 L | ₹-79.59 Cr | |
| Capital expenditure | ₹-229.71 Cr | — | ₹-19.49 Cr | ₹-14.23 Cr | ₹-10.36 Cr | ₹-14.93 Cr |
| End cash position | ₹12.04 Cr | ₹13.01 Cr | ₹31.72 Cr | ₹31.31 Cr | ₹12.42 Cr | ₹30.19 Cr |
Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22–Sep 24(10Q) | Dec 24 | Mar 25 | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.43% | 73.72% | 73.92% | 73.94% | 74.11% | 74.24% | 74.69% | 74.84% | 74.07% |
| Public | 25.57% | 26.28% | 26.08% | 26.06% | 25.89% | 25.76% | 25.31% | 25.16% | 25.93% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Health X Platform Limited | ₹948.27 Cr | ₹300 | 763.6 | 1.48 | 0.2% | 0.04 | +20.0% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 16
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices